Figure 2.
Hazard ratio of DKA for new users of SGLT2 inhibitors versus comparator AHAs with censoring at the initiation of non‐index AHAs and discontinuation of the index AHA.
Abbreviations: AHA, antihyperglycemic agent; CCAE, IBM® MarketScan® Commercial Database; CI, confidence interval; DKA, diabetic ketoacidosis; DPP‐4, dipeptidyl peptidase‐4; GLP‐1, glucagon‐like peptide‐1; HR, hazard ratio; MDCD, IBM® MarketScan® Multi‐State Medicaid Database; MDCR, IBM® MarketScan® Medicare Supplemental Database; Optum, Optum© De‐identified Clinformatics® Data Mart Database; SGLT2, sodium glucose co‐transporter 2; SU, sulfonylurea; T2DM, type 2 diabetes mellitus; TZD, thiazolidinedione.
*Either no cases in the target and/or comparator cohort or number of cases were too few for the model to converge